

ASX ANNOUNCEMENT

06 September 2021

ANTERIS APPOINTS CHIEF MEDICAL OFFICER

Brisbane, Australia and Minneapolis, USA. Anteris Technologies Ltd (ASX: AVR) (Anteris or the Company) announces the appointment of the internationally recognized Interventional Cardiologist, Dr Chris Meduri MD MPH, as its Chief Medical Officer (CMO).

Dr Meduri is a recognized leader in the field of valvular heart disease, serving as the national principle investigator of several valve trials and on numerous steering committees. He has performed first-in-US and first-in-world procedures, led enrollment in many trials and actively participated in 11 transcatheter early feasibility studies.

“With the rapid progress of the DurAVR™ program, the timing is now right just ahead of our planned early feasibility study to establish the role of CMO. As Chris has been working as an Advisory Board member his transition into the CMO role will be seamless. Whilst still maintaining external clinical practice responsibilities, the additional time commitment from him in this new role will help us advance even further whilst adding greater credibility and profile to our product. Chris is well known and respected within the global cardiology community. We are thrilled he has agreed to be our CMO,” said Anteris’ Chief Executive Officer, Wayne Paterson.

An active member of the Anteris Medical Advisory Board since inception, he contributed significantly to the current development progress of DurAVR™. As a practicing clinician, Dr Meduri has performed more than 1500 TAVR procedures using all currently available products, helped to build post-operative care pathways for TAVR patients and developed an app used to optimize the care of TAVR patients.

“I am honored to take on a broader role with the Anteris team to help deliver on its mission of delivering the world’s most durable heart valve. I look forward to collaborating with the talented team and advisory board to launch the DurAVR™ product and aid in providing a longer-lasting TAVR future for all patients,” Dr Meduri said.

Dr Meduri is a subject matter expert and widely published in areas such as TAVR, mitral valve repair and replacement, tricuspid repair and others. Additionally, he is an active speaker, podium presenter and live case operator at numerous major international cardiac and medical conferences.

Dr Meduri completed his general, interventional and structural heart disease training at Beth Israel Deaconess Medical Center, Harvard Medical School. He completed his Masters in Public Health (MPH) with a focus on Clinical Effectiveness at the Harvard School of Public Health. He completed his internship and residency in Internal Medicine at Duke University.

ENDS

Anteris Technologies Ltd Registered Office:

Toowong Tower, Suite 302, Level 3, 9 Sherwood Rd, Toowong, Queensland, 4066

Customer Service

T +61 1300 550 310 | F +61 1300 972 437 | E info@anteristech.com | W anteristech.com

Brisbane • Minneapolis • Geneva • Malaga



About Anteris Technologies Ltd (ASX: AVR)

Anteris Technologies Ltd is a structural heart company delivering clinically superior and durable solutions through better science and better design. Its focus is on developing next generation technologies that help healthcare professionals create life-changing outcomes for patients.

The Anteris DurAVR™ aortic replacement valve addresses the acute need in terms of superior hemodynamic profile as well as chronic needs in its ability to sustain that profile longer over the lifetime of the patient.

The proven benefits of its ADAPT® tissue technology, paired with DurAVR™'s unique 3D single-piece aortic valve design, has the potential to deliver a functional cure to aortic stenosis patients and provide a much-needed solution to the challenges facing heart surgeons today.

Authorisation and Additional information

This announcement was authorised by Mr Wayne Paterson, Chief Executive Officer.

For more information:

Hannah Howlett
WE Communications
E: WE-AUAnterisTech@we-worldwide.com
P: +61 4 5064 8064
www.anteristech.com
Twitter: @AnterisTech
Facebook: www.facebook.com/AnterisTech